Search details
1.
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
Clin Infect Dis
; 76(2): 201-209, 2023 01 13.
Article
in English
| MEDLINE | ID: mdl-36196614
2.
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Clin Exp Immunol
; 211(3): 280-287, 2023 03 24.
Article
in English
| MEDLINE | ID: mdl-36729167
3.
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Lancet
; 398(10304): 981-990, 2021 09 11.
Article
in English
| MEDLINE | ID: mdl-34480858
4.
'You've Got No Support': The Experiences of Older Male Caregivers When Their Partner Enters Residential Care.
J Gerontol Soc Work
; 65(5): 529-544, 2022 07.
Article
in English
| MEDLINE | ID: mdl-34591745
5.
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
Nat Med
; 29(1): 147-157, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36228659
6.
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.
JCI Insight
; 7(7)2022 04 08.
Article
in English
| MEDLINE | ID: mdl-35192543
7.
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Nat Med
; 27(2): 270-278, 2021 02.
Article
in English
| MEDLINE | ID: mdl-33335323
8.
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.
Lancet HIV
; 8(8): e474-e485, 2021 08.
Article
in English
| MEDLINE | ID: mdl-34153264
9.
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Nat Med
; 27(6): 1116, 2021 Jun.
Article
in English
| MEDLINE | ID: mdl-34021278
Results
1 -
9
de 9
1
Next >
>>